Bone Biologics Corp — Director's Dealing 2024

Jan 19, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2024-01-17

Reporting Person: Frelick Jeff (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-17	Employee Stock Option	$3.61	A	25000	Acquired	2026-01-17	Common Stock (25000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2151	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option	$9540.00	2025-12-27	Common Stock (173)	173	Direct
Employee Stock Option	$12300.00	2026-05-26	Common Stock (44)	44	Direct
Employee Stock Option	$892.80	2025-01-01	Common Stock (208)	208	Direct
Employee Stock Option	$57.60	2025-01-25	Common Stock (157)	157	Direct

Footnotes

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

F2: This option is fully vested as of the date of this report.